Clinical trials: Stem Cell Transplants
Multiple Myeloma
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
This study aims to compare how belantamab behaves in the body when given as an injection under the skin (SC) versus into a vein (IV) in participants with multiple myeloma who are receiving standard of care treatment, to enable…
- Trial name
- DynaMMic-2 (NCT07742527)
- Testing
- Belantamab SC, Belantamab IV, Recombinant Human Hyaluronidase PH20 (rHuPH20)
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Leukemia
G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission
RATIONALE: Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant.
- Trial name
- NCT00233961
- Testing
- filgrastim
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Acute Graft Versus Host Disease
Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease
This study evaluates the safety and effectiveness of two different doses of umbilical cord derived, ex-vivo cultured and expanded Wharton's jelly mesenchymal stem cells (MSCTC-0010) in the treatment of acute Graft versus Host…
- Trial name
- NCT03158896
- Testing
- MSCTC-0010 Dose Escalation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Kansas Medical Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00255710
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Lymphoma
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00521430
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02892695
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Chronic Graft-versus-host Disease
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
Rituximab is an attractive agent to bring to the upfront treatment of chronic graft-versus-host disease (cGVHD) due to its favorable toxicity profile, its proven efficacy in the treatment of steroid-refractory cGVHD, and its…
- Trial name
- NCT01161628
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northside Hospital, Inc.
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
This phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia
- Trial name
- NCT00792948
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine
- Where
- 157 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
Mucopolysaccharidosis Type IH, MPS I
Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome
This is a standard of care treatment guideline for patients with the diagnosis of mucopolysaccharidosis type IH (MPS I, Hurler syndrome) who are being considered as candidates for first hematopoietic stem cell transplantation…
- Conditions
- Mucopolysaccharidosis Type IH, MPS I, Hurler Syndrome
- Trial name
- NCT01572636
- Testing
- Laronidase
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
This phase II trial studies how well carfilzomib and dexamethasone work in treating patients with multiple myeloma who previously underwent a stem cell transplant.
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- CARAMEL 2 (NCT01812720)
- Testing
- carfilzomib, dexamethasone, laboratory biomarker analysis
- Where
- 3 sites in United States
- Sponsor
- Mayo Clinic
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors
The clinical application and effect of ATG based myeloablative conditioning regimen after allogeneic hematopoietic stem cell transplantation in adult patients with aggressive T-cell lymphomas.
- Trial name
- HSCT (NCT02290132)
- Testing
- Rabbit Anti-human Thymocyte Globulin (ATG)
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Stem Cell Transplant Complications, Graft Versus Host Disease, Acute
Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease
The investigators hypothesize that perturbations in the intestinal microbiota following allogeneic hematopoietic stem cell transplantation (HSCT) are essential for the development and propagation of acute graft-versus-host…
- Conditions
- Stem Cell Transplant Complications, Graft Versus Host Disease, Acute, Fecal Microbiota Transplantation
- Trial name
- NCT03214289
- Testing
- Fecal Microbiota Transplantation
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Sheba Medical Center
Severe Combined Immunodeficiency, Transplacental Maternal Engraftment
Sirolimus Prophylaxis for aGVHD in TME SCID
Study Design: SCID infants receiving an unconditioned haploidentical transplant will be started on Sirolimus (0.05 mg/kg/day) day -5 for Acute Graft-Versus-Host Disease (aGVHD) prophylaxis.
- Conditions
- Severe Combined Immunodeficiency, Transplacental Maternal Engraftment, Stem Cell Transplant
- Trial name
- NCT02177760
- Testing
- Sirolimus
- Where
- United States
- Sponsor
- University of California, San Francisco
Stem Cell Transplant Complications, Myeloma
Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT
As the average age of individuals undergoing stem cell transplant continues to increase, challenges associated with balancing the side effects of cancer treatments while also managing other medical conditions develop.
- Conditions
- Stem Cell Transplant Complications, Myeloma, Lymphoma, Allogeneic and Autologous Stem Cell Transplant
- Trial name
- NCT04194840
- Testing
- physical therapy consult, Cognitive Assessment, Cancer Aging Research Group (CARG) assessment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Case Comprehensive Cancer Center
BK Virus Infection
Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- NCT02313844
- Testing
- Viralym-B
- Where
- 2 sites in United States
- Sponsor
- AlloVir
Lymphoma
Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT
Evaluate the safety of natural killer (NK) cell infusion using CD56 monoclonal antibody selected with Miltenyi Biotec system following nonmyeloablative stem cell transplantation (SCT) from mismatched donors.
- Trial name
- NCT00586703
- Testing
- NK-CD56
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- David Rizzieri, MD
Leukemia, Lymphoma
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Unrelated matched donor (cord blood, bone marrow or peripheral blood) allogeneic stem cell transplantation (UDAlloSCT) with either myeloablative or reduced intensity conditioning will be well tolerated and result in a high degree…
- Conditions
- Leukemia, Lymphoma, Bone Marrow Failure Syndromes, Immunodeficiencies
- Trial name
- NCT01050439
- Testing
- UDAlloSCT, Therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Columbia University
Multiple Myeloma
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
The purpose of this study is to induce anti-myeloma responses in patients with high risk or relapsed myeloma using combination chemo- and immunotherapy comprising sequentially: 1) lymphoid and myeloid suppressive conditioning, 2)…
- Trial name
- NCT00089453
- Testing
- Dexamethasone, Cyclophosphamide, Melphalan
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Graft Failure, Stem Cell Transplant Complications
Modified Second Haplo-transplantation for Graft Failure
Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. We previously reported encouraging results with a novel Flu/Cy regimen.
- Trial name
- NCT06512545
- Testing
- second allogeneic stem cell transplantation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peking University People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.